Strategic Partnerships Manager, Oncology Providers
Pubblicato il 12-08-2026 - Massive Bio in Città Metropolitana di Torino
About Massive BioEvery cancer patient deserves access to treatment options. Massive Bio is an AI-powered precision medicine platform transforming how cancer patients discover and access clinical trials by eliminating the barriers of geography, financial constraints, and information asymmetry that have historically limited enrollment.
Scopra esattamente quali competenze, esperienze e qualifiche sono necessarie per avere successo in questo ruolo prima di candidarsi.
Founded in 2015 and headquartered in US, Massive Bio is scaling its impact globally by powering operations across multiple countries and bringing innovative cancer treatment options to a rapidly growing and diverse population of patients. Through our proprietary AI platform, we connect individuals to clinical trials worldwide and partner with leading pharmaceutical companies, contract research organizations (CROs), and healthcare systems to accelerate drug development and expand equitable access to cutting-edge therapies. We're recognised as a leader in health-tech innovation.
Massive Bio was featured as #4 in Fast Company's Startup 100 list for Turkey and has raised $24M in total funding from impact-driven investors including Revo Capital, the International Finance Corporation, and Cavendish Impact Foundation, validating both our business model and our mission-driven approach.
Role OverviewWe're seeking a Strategic Partnerships Manager to spearhead Massive Bio's partnership strategy and market development in Italy. This role is critical to our European expansion, focusing on building transformative relationships with pharmaceutical companies, research institutions, and healthcare providers to advance oncology clinical trials.
Key ResponsibilitiesPartnership Development & Strategy
- Design and execute comprehensive partnership strategies with pharmaceutical companies, biotech firms, and CROs across Italy
- Lead high-stakes negotiations with C-level executives and research heads at major pharmaceutical org